Collateral damage of NUDT15 deficiency in cancer provides a cancer pharmacogenetic therapeutic window with thiopurines
Jacob C. Massey, Joseph Magagnoli, S. Scott Sutton, Phillip Buckhaults, Michael D. Wyatt
The paper identifies that NUDT15 loss in cancer cells creates a therapeutic window for thiopurines, showing increased sensitivity in cancer cell lines and reduced prostate cancer incidence with thiopurine and xanthine oxidase inhibitor co-treatment.
bioRxiv · Apr 8, 2024 · PreprintPharmacology & Toxicology